Piper Sandler reiterates Overweight rating on Axsome Therapeutics, $258 price target
Piper Sandler maintained an Overweight rating on Axsome Therapeutics with a $258 price target, implying a 20.4% upside from the Sep 17 close of $214.28. The firm cited strong new prescription growth and a positive future outlook for the company, driven by increased demand in the MDD segment and early contributions from Alzheimer's disease agitation treatments.
How this was made
The 30-second read
Why it matters
The main tradable element is the explicit price target and implied upside, which can influence positioning, but the piece does not report new clinical, regulatory, or financial results.
Market read
Valuation and sentiment update for AXSM based on an analyst reiteration, with limited evidence of new primary information.
What to watch
Traders may discount the note if upcoming catalysts (conversion rates, seasonal MDD strength, sales expansion) are not backed by newly disclosed metrics in this article.
Background
The article summarizes a Piper Sandler analyst note reiterating Overweight on Axsome Therapeutics with a $258 target, anchored to recent NBRx growth and expected conversion and seasonal drivers.
Ticker impact
Piper Sandler reiterates an Overweight rating on Axsome Therapeutics and sets a $258 price target, implying ~20.4% upside from the Sep 17 close.
Near-term support for AXSM sentiment, with limited follow-through unless new primary data or guidance emerges.
Analyst reiterations can move price at the margin, but the article provides no new trial, regulatory, or earnings datapoint, only a thesis around NBRx growth and sales execution.
Market effects
Incremental sentiment tailwind for specialty pharma/neurology depression and Alzheimer’s-adjacent names, but no direct sector-wide catalyst is disclosed.
None indicated.
None indicated.
Counterpoint
If the NBRx acceleration described is already known or not yet reflected in reported revenue, the reiterated target may lag reality and fail to sustain upside.
Key entities
- companyAxsome Therapeutics
Subject of the analyst reiteration and price target; thesis centers on NBRx growth acceleration and expected revenue conversion.
- analyst_firmPiper Sandler
Brokerage issuing the reiterated Overweight rating and $258 price target.
